<DOC>
	<DOCNO>NCT02218476</DOCNO>
	<brief_summary>The study perform 50 APS ( antiphospholipid Syndrome ) patient , randomize receive either CoQ10 ( 200mg/day ) placebo one month . Blood drawn time 0 end treatment . Studies conduct plasma purified leukocyte APS . Design : 1 ) Study endothelial function : 2 ) Analysis change operate various prothrombotic/proinflammatory parameter associate intracellular signalling . 3 ) Analysis mitochondrial ultra structure activity ; mitochondrial antioxidant system characterization ; Expression level activity transcription factors/proteins involve oxidative stress ( Foxo 3 , NFkB , Nrf2 ) , Quantification CoQ10 ( Coenzyme Q10 ) . 4 ) Biomarkers oxidative stress . 5 ) miRNAs microarrays , RT-PCR validation correlation/association study . 6 ) Induction over-expression miRNAs interest ; luciferase construct . 7 ) Studies methylation .</brief_summary>
	<brief_title>Beneficial Effects Coenzyme Q10 Treatment Mitochondrial Dysfunction Oxidative Stress Associated Atherothrombosis Developement Antiphospholipidid Syndrome Patients</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<criteria>1 . Patients fulfil Sidney criterion APS ( antiphospholipid Syndrome ) ( Miyakis S et al. , J Thromb Haemost 2006 ; 4:295306 ) 2 . Age 18 year 3 . Written inform consent 1 . Acute Liver Disease . 2 . Severe renal impairment 3 . Acute arterial venous thrombosis episode last 3 month 4 . Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>